MedTrace Logo

Exparel PK and Breast Milk Excretion

NCT03526419 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-09-25

No results posted yet for this study

Summary

Investigate the pharmacokinetics of Liposomal Bupivacaine and its excretion in breast milk in patients undergoing TAP block after their scheduled C -section delivery

Conditions

  • Milk Expression, Breast

Interventions

DRUG

Bupivacaine liposome

blood and milk samples will be obtained from those subjects after TAP block

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-09-01
Completion
2019-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526419 on ClinicalTrials.gov